# KLOW Peptide Dosage in the Research Literature | KLOW peptide > KLOW Peptide Dosage in the Research Literature: no validated human dose exists for the blend, and the four components' divergent half-lives mean no single 'KLOW dose' holds all four at matched exposures. Four peptides, four different clearance rates, one vial. We map the component-level research doses — and the pharmacokinetic mismatch that means there is no single additive KLOW dose to begin with. ## In plain English There is no validated human dosage for KLOW peptide, and this page does not supply one. Picture the four peptides as four stars hung at different heights: they enter and leave the body at very different speeds, so a single shared dose cannot keep all four bright at once. The research vial most people cite is an 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — reconstituted (mixed back into liquid) with bacteriostatic water for laboratory handling. But you cannot add up four separate research doses into one "KLOW dose," because the components were studied separately, in different species, by different routes. What follows describes what was administered in the studies and the routes researchers used — not instructions for any person. ## KLOW dosage and the pharmacokinetic-mismatch problem ## KLOW dosage and the pharmacokinetic-mismatch problem The canonical research vial is an 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — reconstituted with bacteriostatic water for laboratory handling. That ratio describes the contents of the vial; it is not a dose for a person, and no validated human dose exists for the blend. The deeper problem is pharmacokinetic. The four peptides clear the body at markedly different rates. BPC-157's first formal PK study reported a very short elimination half-life — under about 30 minutes — with linear kinetics and modest intramuscular bioavailability [16]. The two tripeptides, KPV and GHK-Cu, are smaller still and clear even faster. The TB-500 fragment behaves differently from the native thymosin beta-4 whose half-life lengthened with dose in a human trial [15]. Stack those facts together and one conclusion is unavoidable: a single co-formulated dose cannot hold all four components at matched exposures. This is a structural feature of any one-vial four-peptide product, not a tuning problem. ## Component-level research doses Because there is no blend dose, the only real numbers are per-component, and they are not additive. In rat tendon studies, BPC-157 was administered at 10 μg, 10 ng or 10 pg per rat, usually by once-daily intraperitoneal injection [2]. Thymosin beta-4, the parent protein of TB-500, was active in wound assays at as little as 10 pg in migration work and tested topically and intraperitoneally in vivo [1]; in a human Phase 1 trial it was given intravenously at 42 to 1260 mg [15]. KPV was studied at 10 nM in cell culture and 100 μM in mouse drinking water [3]. GHK-Cu acts at nanomolar concentrations in vitro and as topical formulations clinically [4]. These figures span species, routes and units that do not convert into a single human milligram-per-day number. ## Dosage and frequency in the research literature ### Dosage and frequency in the research literature Neither dose nor frequency is validated for the blend. The components' divergent half-lives — BPC-157 under about 30 minutes [16], the tripeptides faster, the TB-500 fragment distinct from native thymosin beta-4 — mean no single schedule keeps all four at matched exposures [15]. In the component literature, BPC-157 tendon work used once-daily dosing [2], but frequency was set per study and per species, never as a human protocol. Any "X times per week" figure circulating for KLOW is community convention, not a validated finding. ## Routes studied in the research literature ### Where do you inject KLOW peptide? There is no validated human protocol for the blend, so this is a map of routes studied at the component level, not an administration instruction. Subcutaneous and intramuscular injection appear in the research-handling literature. Beyond that, the components diverge: GHK-Cu has extensive topical study — copper applied as GHK-Cu penetrated dermatomed skin and formed a measurable dermal depot over 48 hours [17] — while KPV and BPC-157 have oral and targeted-delivery work, and BPC-157 has intra-articular case-series data [13]. The blend's copper(II) content also raises a theoretical compatibility consideration when co-dissolved with the other three peptides, a point not formally characterized for this mixture. ## How do you reconstitute and how often? ### How do you reconstitute KLOW peptide? The lyophilized (freeze-dried) blend is typically reconstituted with bacteriostatic water for laboratory handling and the solution refrigerated. The copper(II) in GHK-Cu can take part in redox chemistry, a theoretical compatibility consideration when it is co-dissolved with the other peptides — one that has not been formally characterized for this specific mixture [4]. ### How often should you take KLOW peptide? No validated frequency exists. The pharmacokinetic mismatch is the reason: BPC-157's elimination half-life is under about 30 minutes [16] and the tripeptides clear faster still, so no single co-formulated schedule keeps all four components at matched exposures. The dose-context picture connects directly to [reported effects and safety](/effects). --- A desert-night almanac that reads the four-peptide KLOW blend one star at a time — KPV, GHK-Cu, BPC-157 and TB-500 each kept on its own studies, with the lines between them left dotted because no controlled trial has ever joined them.